Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)-Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Kim, Tae Min; Hou, Jing-Zhou; Gaballa, Sameh; Nair, Ranjit; Maruyama, Dai; Izutsu, Koji; Devata, Sumana; Yoon, Dok Hyun; Kim, Won-Seog; Sawalha, Yazeed; Jacobs, Ryan; Hawkes, Eliza; Wang, Ming-Chung; Tam, Constantine; Stevens, Don; Yokoyama, Hisayuki; Kim, Jin Seok; Matasar, Matthew; Ramakrishnan, Aravind; Brennan, Denise; Sermer, David; Lesley, Robin; Zhu, Xu (sue); Obrocea, Mihail; Cho, Seok-Goo

doi:10.1182/blood-2025-5514

상세 보기

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)-Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Kim, Tae Min;
Hou, Jing-Zhou;
Gaballa, Sameh;
Nair, Ranjit;
Maruyama, Dai;
... Kim, Won-Seog;
외 19명

Citations

WEB OF SCIENCE

0

제목: Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)-Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

저자: Kim, Tae Min; Hou, Jing-Zhou; Gaballa, Sameh; Nair, Ranjit; Maruyama, Dai; Izutsu, Koji; Devata, Sumana; Yoon, Dok Hyun; Kim, Won-Seog; Sawalha, Yazeed; Jacobs, Ryan; Hawkes, Eliza; Wang, Ming-Chung; Tam, Constantine; Stevens, Don; Yokoyama, Hisayuki; Kim, Jin Seok; Matasar, Matthew; Ramakrishnan, Aravind; Brennan, Denise; Sermer, David; Lesley, Robin; Zhu, Xu (sue); Obrocea, Mihail; Cho, Seok-Goo

DOI: 10.1182/blood-2025-5514

발행일: 2025-11-03

유형: Meeting Abstract

저널명: Blood

권: 146

@

상세 보기